Brief: Revive Therapeutics Expands Research Partnership For Novel Formulation Development And Clinical Research Of Psilocybin
12/06/2020 14:18
June 12 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS EXPANDS RESEARCH PARTNERSHIP FOR NOVEL
FORMULATION DEVELOPMENT AND CLINICAL RESEARCH OF PSILOCYBIN WITH
THE UNIVERSITY OF WISCONSIN-MADISON
Source text for Eikon: ID:nGNX3nygR
Further company coverage: RVV.CD
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure